Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00074425 · ClinicalTrials.gov registry record · Phase 2
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 3,101
- Enrollment target
NCT00074425 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,101 participants.
The verdict
NCT00074425, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,101 participants
- Enrollment target
Study Summary
The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and effectiveness of these gels.
Interventions
- DRUG Placebo gel
- DRUG BufferGel
- DRUG PRO 2000/5 Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,101 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00074425
The ClinicalTrials.gov registry entry for NCT00074425 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3,101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo gel is the first listed.
NCT00074425 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00074425 about?
NCT00074425 is a clinical study titled "BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women". The majority of HIV infected people worldwide became infected with the virus through heterosexual contact. BufferGel and PRO 2000 Gel are vaginal gels designed to prevent women from becoming infected with HIV during sexual intercourse with an HIV infected partner. This study will test the safety and...
What is the current status of trial NCT00074425?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,101 participants. The study started on 2005-01. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00074425?
The interventions under investigation include: Placebo gel (DRUG), BufferGel (DRUG), PRO 2000/5 Gel (DRUG).
Who is sponsoring clinical trial NCT00074425?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.